Abstract:Disease-specific autoantibodies are considered the most important biomarkers for systemic sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis. Anti-nuclear antibodies (ANA), occurring in subjects with isolated Raynuad's phenomenon, are considered the strongest independent predictors of definite SSc and digital microvascular damage, as observed by nailfold videocapillaroscopy. ANA are present in more than 90% of SSc, but ANA negativity does not exclude SSc diagnosis: a little rate of SSc ANA negative exists and shows a distinct subtype of disease, with less vasculopathy, but more frequent lower gastrointestinal involvement and severe disease course. Anti-centromere, anti-Th/To, and anti-Topoisomerase I antibodies could be considered as classical biomarkers, covering about 60% of SSc and defining patients with well-described cardio-pulmonary complications. In particular, anti-Topoisomerase I represent a risk factor for development of diffuse cutaneous involvement and digital ulcers in the first 3 years of disease, as well as severe interstitial lung disease (ILD). Anti-RNA polymerase III is a biomarker with new clinical implications: very rapid skin thickness progression, gastric antral vascular ectasia, the occurrence of synchronous cancers, and possible association with silicone breast implants rupture. Moreover, novel SSc specific autoantibodies have been globally described in about 10% of "seronegative" SSc patients: anti-elF2B, anti-RuvBL1/2 complex, anti-U11/U12 RNP, and anti-BICD2 depict specific SSc subtypes with severe organ complications. Many autoantibodies could be considered markers of overlap syndromes, including SSc. Anti-Ku are found in 2-7% of SSc, strictly defining the PM/SSc overlap. They are associated with synovitis, joint contractures, myositis, and negatively associated with vascular manifestation of disease. Anti-U3RNP are associated with a well-defined clinical phenotype: Afro-Caribbean male patients, younger at diagnosis, and higher risk of pulmonary hypertension and gastrointestinal involvement. Anti-PM/Scl define SSc patients with high frequency of ILD, calcinosis, dermatomyositis skin changes, and severe myositis. The accurate detection of autoantibodies SSc specific and associated with overlap syndromes is crucial for patients' stratification. ANA should be correctly identified using indirect immunofluorescent assay and a standardized way of patterns' interpretation. The gold-standard technique for autoantibodies' identification in SSc is still considered immunoprecipitation, for its high sensitivity and specificity, but other assays have been widely used in routine practice. The identification of SSc autoantibodies with high diagnostic specificity and high predictive value is mandatory for early diagnosis, a specific follow-up and the possible definition of the best therapy for every SSc subsets. In addition, the validation of novel autoantibodies is mandatory in wider cohorts in order to restrict the gap of so-called seronegative SSc patients.

Immune Mechanisms and Biomarkers in Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Immunological pathogenesis and treatment of systemic lupus erythematosus

Biomarkers for systemic lupus erythematosus - a focus on organ damage

A Comprehensive Review of Immune-Mediated Dermatopathology in Systemic Lupus Erythematosus.

Precision medicine in systemic lupus erythematosus

Systemic lupus erythematosus: a clinical update

Immmunometabolism of systemic lupus erythematosus

Immunopathogenesis of systemic lupus erythematosus: An update

Biomarkers in Systemic Sclerosis: An Overview

The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?

Organ-specific biomarkers in lupus.

Possible novel biomarkers of organ involvement in systemic lupus erythematosus

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Update οn the diagnosis and management of systemic lupus erythematosus

Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers

Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment

Epigenetics and Systemic Lupus Erythematosus: Unmet Needs

LABORATORY BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus

A cellular overview of immunometabolism in systemic lupus erythematosus